---
title: "DaVita Statement on Government's Kidney Care Choices (KCC) Model Updates | DVA Stock News"
description: "DaVita, a kidney care company, praised the Center for Medicare and Medicaid Innovation's (CMMI) decision to extend the Kidney Care Choices (KCC) Model for another year. Misha Palecek, DaVita's chief t"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/242645062.md"
published_at: "2025-05-30T18:35:00.000Z"
---

# DaVita Statement on Government's Kidney Care Choices (KCC) Model Updates | DVA Stock News

> DaVita, a kidney care company, praised the Center for Medicare and Medicaid Innovation's (CMMI) decision to extend the Kidney Care Choices (KCC) Model for another year. Misha Palecek, DaVita's chief transformation officer, highlighted the program's focus on value-based care, which has led to improved health outcomes and increased patient engagement. DaVita has expanded its value-based care arrangements from 11 to 22 Kidney Contracting Entities (KCEs) since 2022, resulting in more transplants and better dialysis access for patients. DaVita aims to set a new standard in kidney care through integrated systems with nephrology partners.

, /PRNewswire/ --DaVita, a comprehensive kidney care company, issued the following statement in response toupdates this week from the Center for Medicare and Medicaid Innovation (CMMI) related to its Kidney Care Choices (KCC) Model. It can be attributed to Misha Palecek, chief transformation officer for DaVita.

*"As a dedicated participant in the government's value-based care initiative and a pioneer in this field for the last twenty years, we applaud CMMI's decision to extend the Kidney Care Choices (KCC) Model for an additional year. We believe the investments made by CMMI and participants alike will result in long-term savings in the upcoming years. The program's emphasis on comprehensive, collaborative care and patient engagement is driving encouraging health outcomes. DaVita is committed to establishing a new standard for kidney care through integrated care systems alongside our nephrology partners."*

Together with participating nephrologists, DaVita launched 11 value-based care arrangements in 2022 and has since doubled that footprint to 22 Kidney Contracting Entities (KCEs). A recent report demonstrates that these value-based care arrangements result in increased transplantation, more patients dialyzing with an optimal access in place, and more patients dialyzing at home.

To learn more about DaVitaIntegrated Kidney Care programs, visit DaVita.com/Innovation.

About DaVita Inc.  
DaVita (NYSE: DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, DaVita has been a leader in clinical quality and innovation for 25 years. DaVita cares for patients at every stage and setting along their kidney health journey—from slowing the progression of kidney disease to helping to support transplantation, from acute hospital care to dialysis at home. As of March 31, 2025, DaVita served approximately 282,000 patients at 3,173 outpatient dialysis centers, of which 2,661 centers were located intheUnited States and 512 centers were located in 13 other countries worldwide. DaVita has reduced hospitalizations, improved mortality, helped improve health access and worked collaboratively to propel the kidney care community to adopt a higher quality standard of care for all patients, everywhere.To learn more, visitDaVita.com/About.

**Media Contact**

Newsroom@davita.com

SOURCE DaVita

### Related Stocks

- [DVA.US - DaVita](https://longbridge.com/en/quote/DVA.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 达维塔保健｜10-K：2025 财年营收 136 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/275658570.md) |
| 达维塔保健｜8-K：2025 财年 Q4 营收 36.2 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/274558142.md) |
| 达维塔公布其全年债务费用为 5.8 亿美元，同比增加 23.4% | 达维塔公布了其 2025 财年的财务结果，显示债务费用为 5.8 亿美元，增长了 23.4%。该公司在税前持续经营收入为 10.2 亿美元，经营活动产生的净现金为 18.9 亿美元。所得税费用为 2.96 亿美元，有效税率为 29.1%。达 | [Link](https://longbridge.com/en/news/275657297.md) |
| 在达维塔（DVA）股价长期疲软且公允价值预估被低估后进行评估 | 达维塔 (DVA) 的股价经历了显著的疲软，过去一年总回报下降了 35.8%。目前交易价格为 105.84 美元，相较于 143 美元的公允价值估计被认为是低估的。分析师的共识目标价为 153.5 美元，范围在 137.0 美元到 186. | [Link](https://longbridge.com/en/news/272864688.md) |
| 社区健康体验：达维塔保健及其合作伙伴正在将健康服务更贴近家庭 | 达维塔与美国糖尿病协会和 YMCA 等组织合作，推出了社区健康体验计划，以改善资源匮乏社区的医疗服务获取。该倡议在 2025 年于奥兰多、休斯顿和洛杉矶的熟悉社区中心提供了免费的健康筛查和教育资源。超过 1,100 名社区成员参与了该项目， | [Link](https://longbridge.com/en/news/272432501.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.